Jazz Pharmaceuticals licensed SAN2355 to Saniona for development on August 29, 2025.
4 reports, 4 independent
Updated Aug 29
Gone quiet
Reached 4 outlets in its first 24 hours
- Reports
- 4
- Developments
- 1
- Repetition
- 75%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Jazz Pharmaceuticals licensed SAN2355 to Saniona for development on August 29, 2025.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Jazz Pharmaceuticals
Irish tax-registered pharmaceutical corporation
-
Saniona
company located in Boston, USA and Glostrup, Denmark
Nothing else this week.
Related events
Coverage
Newest first; wire copies grouped- Insider MonkeyJazz Pharmaceuticals (JAZZ) Sings License with Saniona for SAN2355 Jazz Pharmaceuticals plc (NASDAQ:JAZZ) is one of the Best Mid Cap Growth Stocks to Buy According to Hedge Funds. On August 20, Jazz
- Simply Wall St.Saniona Partnership and CEO Change Might Change The Case For Investing In Jazz Pharmaceuticals (JAZZ) On August 20, 2025, Saniona announced an exclusive global license agreement granting Jazz Pharmac
- ZacksJAZZ Inks $1B Licensing Deal With Saniona for Epilepsy Drug JAZZ Pharmaceuticals JAZZ announced that it has signed an agreement with Denmark-based biopharmaceutical company Saniona to acquire worldwi
- PR NewswireJazz Pharmaceuticals Enters Exclusive Licensing Agreement with Saniona to Develop and Commercialize SAN2355 Saniona to receive US $42.5 million upfront; potential for development, regulatory and sale